Neumirna Therapeutics
Copenhagen
About Neumirna Therapeutics
Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $20.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2025)
- Website: neumirna.com
- Phone: [email protected]
Industries & Categories
Health Care, Neuroscience, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neumirna-therapeutics-58297 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.